Acridone suppresses the proliferation of human breast cancer cells in vitro via ATP-binding cassette subfamily G member 2

Xu,Licheng; Li,Shuyan; Liang,Zhi; Lin,Haixia; Fu,Rongzhan

doi:10.3892/ol.2017.7583

Acridone suppresses the proliferation of human breast cancer cells in vitro via ATP-binding cassette subfamily G member 2

Authors:
- Licheng Xu
- Shuyan Li
- Zhi Liang
- Haixia Lin
- Rongzhan Fu
View Affiliations

Affiliations: Department of Breast Surgery, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China, Department of Endocrinology, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China, Department of Breast Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: December 11, 2017 https://doi.org/10.3892/ol.2017.7583
Pages: 2651-2654

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the past decades, the tricyclic acridone ring system has become a focus of major research by medicinal chemists due to the biological significance of this moiety in drug design and discovery. Acridone has substantial bio‑potential since it performs crucial functions, including antibacterial, antimalarial, antiviral and anti‑neoplastic activities. However, the anticancer effect and the underlying mechanisms of acridone on breast cancer cells remains unclear. In the present study, the anti‑tumor function and the underlying mechanisms of acridone were evaluated in vitro. Firstly, an MTT assay was used to evaluate the inhibitory effect of acridone. Subsequently, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to investigate whether ATP binding cassette subfamily G member 2 (ABCG2) was associated with the function of acridone. Finally, western blotting was used to confirm the results of RT‑qPCR. The present study demonstrated that acridone may decrease the proliferation of MDA‑MB‑231 cells dose‑dependently. Further experiments revealed that acridone may downregulate the mRNA and protein expression levels of ABCG2, supporting the potential application of acridone in breast cancer treatment. These findings suggested that acridone is a potential agent in the treatment of human breast cancer.

View Figures

View References

1	Coughlin SS and Ekwueme DU: Breast cancer as a global health concern. Cancer Epidemiol. 33:315–318. 2009. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kasami M, Uematsu T, Honda M, Yabuzaki T, Sanuki J, Uchida Y and Sugimura H: Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast. 17:523–527. 2008. View Article : Google Scholar : PubMed/NCBI
4	Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005. View Article : Google Scholar : PubMed/NCBI
5	Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL and Harris JR: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 26:2373–2378. 2008. View Article : Google Scholar : PubMed/NCBI
6	Huang CS, Lin CH, Lu YS and Shen CY: Unique features of breast cancer in Asian women-breast cancer in Taiwan as an example. J Steroid Biochem Mol Biol. 118:300–303. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277. 2010. View Article : Google Scholar : PubMed/NCBI
8	Morgan G, Ward R and Barton M: The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 16:549–560. 2004. View Article : Google Scholar : PubMed/NCBI
9	Kuczynski EA, Sargent DJ, Grothey A and Kerbel RS: Drug rechallenge and treatment beyond progression-implications for drug resistance. Nat Rev Clin Oncol. 10:571–587. 2013. View Article : Google Scholar : PubMed/NCBI
10	Zambre VP, Murumkar PR, Giridhar R and Yadav MR: Development of highly predictive 3D-QSAR CoMSIA models for anthraquinone and acridone derivatives as telomerase inhibitors targeting G-quadruplex DNA telomere. J Mol Graph Model. 29:229–239. 2010. View Article : Google Scholar : PubMed/NCBI
11	Cuenca F, Moore MJ, Johnson K, Guyen B, De Cian A and Neidle S: Design, synthesis and evaluation of 4,5-di-substituted acridone ligands with high G-quadruplex affinity and selectivity, together with low toxicity to normal cells. Bioorg Med Chem Lett. 19:5109–5113. 2009. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Su TL, Kohler B, Chou TC, Chun MW and Watanabe KA: Synthesis of the acridone alkaloids glyfoline and congeners. Structure-activity relationship studies of cytotoxic acridones. J Med Chem. 35:2703–2710. 1992. View Article : Google Scholar : PubMed/NCBI
14	Cholewiński G, Dzierzbicka K and Kolodziejczyk AM: Natural and synthetic acridines/acridones as antitumor agents: Their biological activities and methods of synthesis. Pharmacol Rep. 63:305–336. 2011. View Article : Google Scholar : PubMed/NCBI
15	Koba M and Baczek T: Physicochemical interaction of antitumor acridinone derivatives with DNA in view of QSAR studies. Med Chem Res. 20:1385–1393. 2011. View Article : Google Scholar : PubMed/NCBI
16	Prasad VV Rajendra, Peters GJ, Lemos C, Kathmann I and Mayur YC: Cytotoxicity studies of some novel fluoro acridone derivatives against sensitive and resistant cancer cell lines and their mechanistic studies. Eur J Pharm Sci. 43:217–224. 2011. View Article : Google Scholar : PubMed/NCBI
17	Yamamoto N, Furukawa H, Ito Y, Yoshida S, Maeno K and Nishiyama Y: Anti-herpesvirus activity of citrusinine-I, a new acridone alkaloid, and related compounds. Antiviral Res. 12:21–36. 1989. View Article : Google Scholar : PubMed/NCBI
18	Basco LK, Mitaku S, Skaltsounis AL, Ravelomanantsoa N, Tillequin F, Koch M and Le Bras J: In vitro activities of furoquinoline and acridone alkaloids against Plasmodium falciparum. Antimicrob Agents Chemother. 38:1169–1171. 1994. View Article : Google Scholar : PubMed/NCBI
19	Valdés AF: Acridine and acridinones: Old and new structures with antimalarial activity. Open Med Chem J. 5:11–20. 2011. View Article : Google Scholar : PubMed/NCBI
20	Stankiewicz-Drogoń A, Dörner B, Erker T and Boguszewska-Chachulska AM: Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication. J Med Chem. 53:3117–3126. 2010. View Article : Google Scholar : PubMed/NCBI
21	Chukaew A, Ponglimanont C, Karalai C and Tewtrakul S: Potential anti-allergic acridone alkaloids from the roots of Atalantia monophylla. Phytochemistry. 69:2616–2620. 2008. View Article : Google Scholar : PubMed/NCBI
22	Delmas F, Avellaneda A, Di Giorgio C, Robin M, De Clercq E, Timon-David P and Galy JP: Synthesis and antileishmanial activity of (1,3-benzothiazol-2-yl) amino-9-(10H)-acridinone derivatives. Eur J Med Chem. 39:685–690. 2004. View Article : Google Scholar : PubMed/NCBI
23	Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
24	Pérez-Tomás R: Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 13:1859–1876. 2006. View Article : Google Scholar : PubMed/NCBI
25	Wu CP, Ohnuma S and Ambudkar SV: Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 12:609–620. 2011. View Article : Google Scholar : PubMed/NCBI